Hairloss Study Abstract: Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.

Title: Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Title Abreviation: Anticancer Drugs		Date of Pub: 1996 Jan
Author: Blackledge G; Kolvenbag G; Nash A;
Issue/Part/Supplement: 1	Volume Issue: 7		Pagination: 27-34
MESH Headings: Adult; Aged; Aged, 80 and over; Androgen Antagonists (AD/AE/TU); Anilides (AD/TU); Antineoplastic Agents, Hormonal (AE/TU); Combined Modality Therapy; Flutamide (AE/TU); Human; Male; Middle Age; Neoplasms, Hormone-Dependent (DT/SU); Orchiectomy; Prostatic Neoplasms (DT/SU); Randomized Controlled Trials; -RN-;
Journal Title Code: A9F	Publication Type: JOURNAL ARTICLE
Date of Entry: 961114N	Entry Month: 9701
Country: ENGLAND	Index Priority: 2
Language: Eng	Unique Identifier: 96361722
Unique Identifier: 96361722	ISSN: 0959-4973
Abstract: Maximum androgen blockade, a relatively recent development in the treatment of prostate cancer, combines medical or surgical castration with antiandrogen therapy. A large randomized study comparing the non-steroidal antiandrogen, bicalutamide, with flutamide, each in combination with luteinizing hormone-releasing hormone (LHRH) analogs, showed that after a median follow-up of 49 weeks, the time to treatment failure was significantly longer for the bicalutamide patients compared with the flutamide patients (p = 0.005). After a median follow up to 95 weeks, bicalutamide in combination with LHRH analog therapy produced at least equivalent efficacy with flutamide in combination with LHRH analog therapy in terms of time to treatment failure and equivalent efficacy in terms of survival. The tolerability profile of bicalutamide, as based on reported findings and a literature review, indicates a superior tolerability to that of currently available antiandrogens, particularly with respect to diarrhea with a low incidence of treatment-related withdrawals.
Abstract By: Author
Address: Medical Research Department, ZENECA Pharmaceuticals Ltd, Mereside, Macclesfield, UK.
Number of References: 38